CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Continuing Investigation into the Offer

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, raising concerns about the fairness of the transaction and the board's decision-making process [1][3]. Transaction Details - On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie for $45.00 per share in cash, valuing Cerevel at approximately$8.7 billion [2]. - The transaction has been approved by the boards of directors of both companies and is expected to close in mid-2024 [2]. Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the acquisition [3]. - Current shareholders are encouraged to submit their information to understand their rights in this situation [3][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [5].